EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers

Van K Morris iD, Amir Jazaeri, Shannon N Westin, Curtis Pettaway, Solly George, Ryan W Huey, Michaela Grinsfelder, Aaron Shafer, Benny Johnson iD, David Vining, Ming Guo iD, Bryan Fellman und 1 weitere

The Oncologist · 05.07.2023 · 28 (7) · 618-623

DOI: 10.1093/oncolo/oyad085 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 27.04.2023. Verfasst von Van K Morris und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human papillomavirus (HPV) types 16/18 drive oncogenesis for most patients with cervical, anal, and penile cancers. MEDI0457, a therapeutic DNA vaccine containing plasmids for E6 and E7 HPV-16/18 viral oncogenes and IL-12 adjuvant, is safe and provokes an immune response against E6/E7. We tested MEDI0457 with the anti-PD-L1 antibody durvalumab for patients with HPV-associated cancers.

Methods

Patients with recurrent/metastatic, treatment-refractory HPV-16/18 cervical cancer, or rare HPV-associated (anal and penile) cancers were eligible. Prior immune checkpoint inhibition was not permitted. Patients received MEDI0457 7 mg intramuscularly (weeks 1, 3, 7, 12, and every 8 weeks thereafter) and durvalumab 1500 mg intravenously every 4 weeks. The primary endpoint was overall response (RECIST 1.1). In this Simon two-stage phase 2 trial (Ho: p < 0.15; Ha: p ≥ 0.35), ≥2 responses were needed in both cervical and non-cervical cohorts during the first stage for the trial to proceed to stage 2 with an additional 25 patients (34 total) enrolled.

Results

Twenty-one patients (12 cervical, 7 anal, and 2 penile) were evaluable for toxicity and 19 for response Overall response rate was 21% (95% CI, 6%-46%) among evaluable patients. Disease control rate was 37% (95% CI, 16%-62%). Median duration of response among responders was 21.8 months (95% CI, 9.7%-not estimable). Median progression-free survival was 4.6 months (95% CI, 2.8%-7.2%). Median overall survival was 17.7 months (95% CI, 7.6%-not estimable). Grades 3-4 treatment-related adverse events occurred in 6 (23%) participants.

Conclusions

The combination of MEDI0457 and durvalumab demonstrated acceptable safety and tolerability in patients with advanced HPV-16/18 cancers. The low ORR among patients with cervical cancer led to study discontinuation despite a clinically meaningful disease control rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsFemaleHumansHuman Papillomavirus VirusesHuman papillomavirus 16Neoplasm Recurrence, LocalHuman papillomavirus 18Antibodies, MonoclonalPapillomavirus Vaccines

Stichwörter der Autor:innen

DNA vaccineHPVanti-PD-L1immunotherapymetastasis

Substanzen

durvalumabAntibodies, MonoclonalMEDI0457Papillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Gynecologic Oncology, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Urology, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Radiology, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Pathology, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Biostatistics, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Van K Morris, Benny Johnson, Ming Guo

Förderung

  • NCI NIH HHS

Zitieren

APA

Morris, V. K., Jazaeri, A., Westin, S. N., Pettaway, C., George, S., Huey, R. W., Grinsfelder, M., Shafer, A., Johnson, B., Vining, D., Guo, M., Fellman, B., & Frumovitz, M. (2023). Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. The Oncologist, 28(7), 618-623. https://doi.org/10.1093/oncolo/oyad085

Vancouver

Morris VK, Jazaeri A, Westin SN, Pettaway C, George S, Huey RW, et al. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. The Oncologist. 2023;28(7):618-623. doi:10.1093/oncolo/oyad085

BibTeX
@article{Morris2023,
  author = {Morris, Van K and Jazaeri, Amir and Westin, Shannon N and Pettaway, Curtis and George, Solly and Huey, Ryan W and Grinsfelder, Michaela and Shafer, Aaron and Johnson, Benny and Vining, David and Guo, Ming and Fellman, Bryan and Frumovitz, Michael},
  title = {Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {7},
  pages = {618--623},
  doi = {10.1093/oncolo/oyad085}
}
Kostenlos starten →